Skip to main content

Table 4 Post-baseline genotypic analysis through Week 48 in the 15 patients in the resistance analysis population

From: Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial

Patient number N[t]RTI backbone Treatment cohort Visit (week) RAMs emerging*
Protease Reverse transcriptase
1 Abacavir plus tenofovir Naïve 24 None None
2 Emtricitabine/tenofovir Naïve 12 None None
3 Emtricitabine/tenofovir Naïve 48 I93I/L I142L/P
4 Emtricitabine/tenofovir Experienced 24 None K22K/R
5 Emtricitabine/tenofovir Naïve 36 R57R/K M184V
6 Emtricitabine/tenofovir Naïve 16 V32V/A, P39P/S K122K/E, D123D/G/N/S, D177D/G, I178M
7 Emtricitabine/tenofovir Naïve 48 None D123D/E
8 Emtricitabine/tenofovir Experienced 48 None K122K/E, A272A/P
9 Emtricitabine/tenofovir Experienced 12 I84I/V E138T, T165A/E, R211R/K
10 Emtricitabine/tenofovir Naïve 8 G86G/E D123N
11 Emtricitabine/tenofovir plus zidovudine Experienced 48 None I195I/L
12 Abacavir plus tenofovir Experienced 36 R41R/K None
13 Emtricitabine/tenofovir Naïve 48 V77V/I E6E/K, E224E/Q, V245Q, T286T/A, V292V/I
14 Emtricitabine/tenofovir plus zidovudine Experienced 48 None E6E/D, V60I
15 Emtricitabine/tenofovir Experienced 36 None M184V
  1. *Compared to screening genotype – emerging primary resistance-associated mutations (RAMs) are shown in bold; N[t]RTI nucleoside/tide reverse transcriptase inhibitor.